Inhaled Sedation in COVID-19-related Acute Respiratory Distress Syndrome (ISCA): an International Research Data Study in the Recent Context of Widespread Disease Resulting From the 2019 (SARS-CoV2) Coronavirus Pandemics (COVID-19)

CompletedOBSERVATIONAL
Enrollment

203

Participants

Timeline

Start Date

June 26, 2020

Primary Completion Date

April 30, 2021

Study Completion Date

April 30, 2021

Conditions
Critically IllnessSedationInvasive Mechanical VentilationAcute Respiratory Distress Syndrome
Interventions
DRUG

Intravenous sedation

Patients will be included retrospectively in the study by local investigators at each participating center. As this is a non-interventional study, sedation practices will be those currently used as standard practices in participating centers, including both intravenous and inhaled sedation practices

DRUG

Inhaled sedation

Patients will be included retrospectively in the study by local investigators at each participating center. As this is a non-interventional study, sedation practices will be those currently used as standard practices in participating centers, including both intravenous and inhaled sedation practices

Trial Locations (12)

63000

CHU, Clermont-Ferrand

75013

Pitié-Salpêtrière Hospital - APHP, Paris

02215

Beth Israel Deaconess Medical Center, Inc., Boston

Unknown

CHU, Brest

Centre Hospitalier, Dunkirk

CH Privé de la Loire, Saint-Etienne

Universitätsklinikum, Bochum

University Medical Center Schleswig-Holstein, Kiel

Universitätsklinikum, Oldenburg

Hospital Clínico Universitario de Valencia, Valencia

Cantonal Hospital, Münsterlingen

Universitätsspital, Zurich

All Listed Sponsors
collaborator

Hospital Clínico Universitario de Valencia

OTHER

collaborator

University Hospital Schleswig-Holstein

OTHER

collaborator

Groupe Hospitalier Pitie-Salpetriere

OTHER

lead

University Hospital, Clermont-Ferrand

OTHER

NCT04383730 - Inhaled Sedation in COVID-19-related Acute Respiratory Distress Syndrome (ISCA): an International Research Data Study in the Recent Context of Widespread Disease Resulting From the 2019 (SARS-CoV2) Coronavirus Pandemics (COVID-19) | Biotech Hunter | Biotech Hunter